Jim C. Oates

TitleDirector, Division of Rheumatology
InstitutionMedical University of South Carolina
DepartmentMedicine
AddressP.O. Box MSC 637
CSB 822
Clinical Science Bldg. - 96 Jonathan Lucas St.
Phone843-792-3484
Fax843-792-7121
ORCID ORCID Icon0000-0002-5426-1359 Additional info
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Jim Oates is a professor and Associate Director in the Division of Rheumatology and Immunology at the Medical University of South Carolina. He received a BS in chemistry at Bates College and a medical degree from Johns Hopkins School of Medicine in 1991. He completed his internship and residency in internal medicine and fellowship in rheumatology at Duke University Medical Center in 1996. He came to the Medical University of South Carolina in 1996 to complete a research fellowship and joined the faculty of the Division of Rheumatology in 1997. He became Chief of the Rheumatology Service at the Ralph H Johnson VA Medical Center in 2007, the Informatics Medical Director of Research and Reporting in 2013, and Vice Chair for Research in the Department of Medicine in 2016.

    Dr. Oates' clinical and research interests are focused on systemic lupus erythematosus. He is involved in clinical trials of therapies for systemic lupus erythematosus and lupus nephritis and is the principal investigator on several studies at MUSC involving noninvasive markers of disease and mechanisms through which disease severity may increase among African-Americans. Dr. Oates is an active member of the M.U.S.C.L.E. Research Group. His translational work is focused on the role of reactive intermediates and oxidative stress in the endothelial dysfunction that leads to atherosclerosis and renal disease in patients with lupus. He is also studying machine learning biomarker models of outcome in lupus nephritis.

    He has supported clinical research at a regional and national level by serving as the President American Federation for Medical Research and the President of the Southern Society for Clinical Investigation, where he also serves as an Associate Editor of its journal, the American Journal of Medical Sciences.

    He has received numerous awards, including Phi Beta Kappa from Bates College, the Four Schools Physician Scientist Training Program Scholarship from the Johns Hopkins School of Medicine, the Senior Rheumatology Scholar Award from the American College of Rheumatology (ACR), the Arthritis Investigator Award from the ACR and its foundation, the Research Education Foundation (REF), the Merck Young Investigator Award, the REF/European League Against Rheumatism International Exchange Award, and the Developing Scholar Award from the Medical University of South Carolina Health Sciences Foundation.

    Dr. Jim Oates is Professor and Director in the Division of Rheumatology and Immunology and Vice Chair for Research in the Department of Medicine at the Medical University of South Carolina. He received a BS in chemistry at Bates College and a medical degree from Johns Hopkins School of Medicine in 1991. He completed his internship and residency in internal medicine and fellowship in rheumatology at Duke University Medical Center in 1996. He came to the Medical University of South Carolina in 1996 to complete a research fellowship and joined the faculty of the Division of Rheumatology in 1997. He became Chief of the Rheumatology Service at the Ralph H Johnson VA Medical Center in 2007, the Informatics Medical Director of Research and Reporting in 2013, and Vice Chair for Research in the Department of Medicine in 2016.

    Dr. Oates' clinical and research interests are focused on systemic lupus erythematosus. He is involved in clinical trials of therapies for systemic lupus erythematosus and lupus nephritis and is the principal investigator on several studies at MUSC involving noninvasive markers of disease and mechanisms through which disease severity may increase among African-Americans. Dr. Oates is an active member of the M.U.S.C.L.E. Research Group. His translational work is focused on the role of reactive intermediates and oxidative stress in the endothelial dysfunction that leads to atherosclerosis and renal disease in patients with lupus. He is also studying machine learning biomarker models of outcome in lupus nephritis.

    He has supported clinical research at a regional and national level by serving as the President American Federation for Medical Research and the President of the Southern Society for Clinical Investigation, where he also serves as an Associate Editor of its journal, the American Journal of Medical Sciences.

    He has received numerous awards, including Phi Beta Kappa from Bates College, the Four Schools Physician Scientist Training Program Scholarship from the Johns Hopkins School of Medicine, the Senior Rheumatology Scholar Award from the American College of Rheumatology (ACR), the Arthritis Investigator Award from the ACR and its foundation, the Research Education Foundation (REF), the Merck Young Investigator Award, the REF/European League Against Rheumatism International Exchange Award, and the Developing Scholar Award from the Medical University of South Carolina Health Sciences Foundation.
    Collapse keywords
    Healthy Volunteer Studies, Autoimmune disease, Lupus

    Collapse ORNG Applications 
    Collapse Featured Videos
    Collapse studies/trials

    Collapse Research 
    Collapse research activities and funding
    R01AR045476     (OATES, JAMES C)Apr 23, 1999 - May 31, 2013
    NIH
    Role of reactive intermediates in lupus nephritis
    Role: Principal Investigator

    K08AR002193     (OATES, JAMES C)Apr 25, 2001 - Feb 28, 2006
    NIH
    Role of nitric oxide and eicosanoids in lupus nepthritis
    Role: Principal Investigator

    R21AR051719     (OATES, JAMES C)Sep 20, 2004 - Jun 30, 2007
    NIH
    Urine protein markers of disease in lupus nephritis
    Role: Principal Investigator

    I01CX000218     (OATES, JAMES C)Apr 1, 2010 - Mar 31, 2014
    NIH
    Urine biomarkers of lupus nephritis pathology and response to therapy
    Role: Principal Investigator

    P60AR062755     (GILKESON, GARY S)Jul 1, 2012 - Jun 30, 2017
    NIH
    MCRC for Rheumatic Diseases in African Americans
    Role: Co-Investigator

    I01CX001248     (OATES, JAMES C)Jul 1, 2016 - Jun 30, 2019
    NIH
    Targeting Pathogenic Endothelial Dysfunction in Systemic Lupus Erythematosus
    Role: Principal Investigator

    P30AR072582     (GILKESON, GARY S)Sep 25, 2017 - Aug 31, 2022
    NIH
    Improving Minority Health in Rheumatic Diseases
    Role: Co-Investigator

    R01AR071947     (TSAO, BETTY P.)May 27, 2018 - Apr 30, 2023
    NIH
    Predictive Biomarkers for disease activity and organ damage in patients with lupus
    Role: Co-Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Ning W, Cheng D, Howe PH, Bian C, Kamen DL, Luo Z, Fu X, Ogunrinde E, Yang L, Wang X, Li QZ, Oates J, Zhang W, White D, Wan Z, Gilkeson GS, Jiang W. Staphylococcus aureus peptidoglycan (PGN) induces pathogenic autoantibody production via autoreactive B cell receptor clonal selection, implications in systemic lupus erythematosus. J Autoimmun. 2022 07; 131:102860. PMID: 35810689.
      Citations:    
    2. Barnado A, Eudy AM, Blaske A, Wheless L, Kirchoff K, Oates JC, Clowse MEB. Developing and Validating Methods to Assemble Systemic Lupus Erythematosus Births in the Electronic Health Record. Arthritis Care Res (Hoboken). 2022 05; 74(5):849-857. PMID: 33253488.
      Citations:    
    3. James WA, Ogunrinde E, Wan Z, Kamen DL, Oates J, Gilkeson GS, Jiang W. A Distinct Plasma Microbiome But Not Gut Microbiome in Patients With Systemic Lupus Erythematosus Compared to Healthy Individuals. J Rheumatol. 2022 06; 49(6):592-597. PMID: 35169056.
      Citations:    
    4. Xu L, Wang L, Shi Y, Deng Y, Oates JC, Kamen DL, Gilkeson GS, Wang F, Zhang M, Tan W, Tsao BP. Up-Regulated Interleukin-10 Induced by E2F Transcription Factor 2-MicroRNA-17-5p Circuitry in Extrafollicular Effector B Cells Contributes to Autoantibody Production in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2022 03; 74(3):496-507. PMID: 34569195.
      Citations:    
    5. Oates JC, Russell DL, Van Beusecum JP. Endothelial cells: potential novel regulators of renal inflammation. Am J Physiol Renal Physiol. 2022 03 01; 322(3):F309-F321. PMID: 35129369.
      Citations:    
    6. Altier J, Oates J, Ward C. Polymyalgia Rheumatica or Late Onset Lupus? A Case Report. J Investig Med High Impact Case Rep. 2022 Jan-Dec; 10:23247096221089493. PMID: 35430913.
      Citations:    
    7. Ginzler E, Guedes Barbosa LS, D'Cruz D, Furie R, Maksimowicz-McKinnon K, Oates J, Santiago MB, Saxena A, Sheikh S, Bass DL, Burriss SW, Gilbride JA, Groark JG, Miller M, Pierce A, Roth DA, Ji B. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2022 01; 74(1):112-123. PMID: 34164944.
      Citations:    
    8. Ayoub I, Wolf BJ, Geng L, Song H, Khatiwada A, Tsao BP, Oates JC, Rovin BH. Prediction models of treatment response in lupus nephritis. Kidney Int. 2022 02; 101(2):379-389. PMID: 34871620.
      Citations:    
    9. White AA, Smalls BL, Ba A, Faith TD, Ramakrishnan V, Johnson H, Rose J, Dismuke-Greer CL, Oates JC, Egede LE, Williams EM. The Effect of Travel Burden on Depression and Anxiety in African American Women Living with Systemic Lupus. Healthcare (Basel). 2021 Nov 05; 9(11). PMID: 34828553.
      Citations:    
    10. White A, Faith TD, Ba A, Loftley A, Ramakrishnan V, Johnson H, Rose J, Dismuke-Greer CL, Oates JC, Egede LE, Williams EM. Support Methodologies for African American Women With Lupus - Comparing Three Methods' Effects on Patient Activation and Coping. Front Psychol. 2021; 12:734390. PMID: 34675844.
      Citations:    
    11. Floyd PT, Oates JC, Acker JW, Warren RW. DEFINING THE MEDICAL RECORD: RELATIONSHIPS OF THE LEGAL MEDICAL RECORD, THE DESIGNATED RECORD SET, AND THE ELECTRONIC HEALTH RECORD. Perspect Health Inf Manag. 2021; 18(4):1h. PMID: 34975357.
      Citations:    
    12. Helget LN, Dillon DJ, Wolf B, Parks LP, Self SE, Bruner ET, Oates EE, Oates JC. Development of a lupus nephritis suboptimal response prediction tool using renal histopathological and clinical laboratory variables at the time of diagnosis. Lupus Sci Med. 2021 08; 8(1). PMID: 34429335.
      Citations:    
    13. Hammad SM, Harden OC, Wilson DA, Twal WO, Nietert PJ, Oates JC. Plasma Sphingolipid Profile Associated With Subclinical Atherosclerosis and Clinical Disease Markers of Systemic Lupus Erythematosus: Potential Predictive Value. Front Immunol. 2021; 12:694318. PMID: 34367153.
      Citations:    
    14. Wang X, Oates JC, Helke KL, Gilkeson GS, Zhang XK. Camptothecin and Topotecan, Inhibitors of Transcription Factor Fli-1 and Topoisomerase, Markedly Ameliorate Lupus Nephritis in (NZB × NZW)F1 Mice and Reduce the Production of Inflammatory Mediators in Human Renal Cells. Arthritis Rheumatol. 2021 08; 73(8):1478-1488. PMID: 33559345.
      Citations:    
    15. White AA, Ba A, Faith TD, Ramakrishnan V, Dismuke-Greer CL, Oates JC, Williams EM. The Care-coordination Approach to Learning Lupus Self-Management: a patient navigator intervention for systemic lupus inpatients. Lupus Sci Med. 2021 05; 8(1). PMID: 33975925.
      Citations:    
    16. Baker Frost D, da Silveira W, Hazard ES, Atanelishvili I, Wilson RC, Flume J, Day KL, Oates JC, Bogatkevich GS, Feghali-Bostwick C, Hardiman G, Ramos PS. Differential DNA Methylation Landscape in Skin Fibroblasts from African Americans with Systemic Sclerosis. Genes (Basel). 2021 01 20; 12(2). PMID: 33498390.
      Citations:    
    17. Luo Z, Alekseyenko AV, Ogunrinde E, Li M, Li QZ, Huang L, Tsao BP, Kamen DL, Oates JC, Li Z, Gilkeson GS, Jiang W. Rigorous Plasma Microbiome Analysis Method Enables Disease Association Discovery in Clinic. Front Microbiol. 2020; 11:613268. PMID: 33488555.
      Citations:    
    18. Wolf BJ, Jiang Y, Wilson SH, Oates JC. Variable selection methods for identifying predictor interactions in data with repeatedly measured binary outcomes. J Clin Transl Sci. 2020 Nov 16; 5(1):e59. PMID: 33948279.
      Citations:    
    19. Russell DL, Oates JC, Markiewicz M. Association Between the Anti-Aging Gene Klotho and Selected Rheumatologic Autoimmune Diseases. Am J Med Sci. 2021 02; 361(2):169-175. PMID: 33349438.
      Citations:    
    20. Oates JC. Charlie Gross (1936-2019). Prog Neurobiol. 2020 12; 195:101935. PMID: 33096125.
      Citations:    
    21. Russell DA, Markiewicz M, Oates JC. Lupus serum induces inflammatory interaction with neutrophils in human glomerular endothelial cells. Lupus Sci Med. 2020 10; 7(1). PMID: 33037079.
      Citations:    
    22. Oates JC. 2020 Southern Society for Clinical Investigation Founders' Medal Award. Am J Med Sci. 2020 Jul; 360(1):83-84. PMID: 32475534.
      Citations:    
    23. Oates JC, Ramakrishnan V, Nietert PJ, Spence JD, Fleury TW, Markiewicz M, Russell DL, Lopes-Virella MF. ASSOCIATIONS BETWEEN ACCELERATED ATHEROSCLEROSIS, OXIDIZED LDL IMMUNE COMPLEXES, AND IN VITRO ENDOTHELIAL DYSFUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS. Trans Am Clin Climatol Assoc. 2020; 131:157-177. PMID: 32675856.
      Citations:    
    24. Hammad SM, Hardin JR, Wilson DA, Twal WO, Nietert PJ, Oates JC. Race disparity in blood sphingolipidomics associated with lupus cardiovascular comorbidity. PLoS One. 2019; 14(11):e0224496. PMID: 31747417.
      Citations:    
    25. Williams EM, Egede L, Oates JC, Dismuke CL, Ramakrishnan V, Faith TD, Johnson H, Rose J. Peer approaches to self-management (PALS): comparing a peer mentoring approach for disease self-management in African American women with lupus with a social support control: study protocol for a randomized controlled trial. Trials. 2019 Aug 23; 20(1):529. PMID: 31443732.
      Citations:    
    26. Zhou Z, Bian C, Luo Z, Guille C, Ogunrinde E, Wu J, Zhao M, Fitting S, Kamen DL, Oates JC, Gilkeson G, Jiang W. Progesterone decreases gut permeability through upregulating occludin expression in primary human gut tissues and Caco-2 cells. Sci Rep. 2019 06 10; 9(1):8367. PMID: 31182728.
      Citations:    
    27. Williams EM, Dismuke CL, Faith TD, Smalls BL, Brown E, Oates JC, Egede LE. Cost-effectiveness of a peer mentoring intervention to improve disease self-management practices and self-efficacy among African American women with systemic lupus erythematosus: analysis of the Peer Approaches to Lupus Self-management (PALS) pilot study. Lupus. 2019 Jul; 28(8):937-944. PMID: 31166867.
      Citations:    
    28. Jones Buie JN, Pleasant Jenkins D, Muise-Helmericks R, Oates JC. L-sepiapterin restores SLE serum-induced markers of endothelial function in endothelial cells. Lupus Sci Med. 2019; 6(1):e000294. PMID: 31168396.
      Citations:    
    29. Faith TD, Flournoy-Floyd M, Ortiz K, Egede LE, Oates JC, Williams EM. My life with lupus: contextual responses of African-American women with systemic lupus participating in a peer mentoring intervention to improve disease self-management. BMJ Open. 2018 11 08; 8(11):e022701. PMID: 30413505.
      Citations:    
    30. Shoaibi A, Obeid JS, Oates JC, Habrat ML, Lenert LA. The association between method of solicitation and patient permissions for use of surplus tissues and contact for future research. JAMIA Open. 2018 Oct; 1(2):195-201. PMID: 30474075.
      Citations:    
    31. Putterman C, Pisetsky DS, Petri M, Caricchio R, Wu AHB, Sanz I, Oates JC, Wallace S, Sorek R, Gerwien R, Safer P, Jakobi-Brook K, Cohen IR. The SLE-key test serological signature: new insights into the course of lupus. Rheumatology (Oxford). 2018 09 01; 57(9):1632-1640. PMID: 29873771.
      Citations:    
    32. Obeid JS, Shoaibi A, Oates JC, Habrat ML, Hughes-Halbert C, Lenert LA. Research participation preferences as expressed through a patient portal: implications of demographic characteristics. JAMIA Open. 2018 Oct; 1(2):202-209. PMID: 30474076.
      Citations:    
    33. Williams EM, Hyer JM, Viswanathan R, Faith TD, Voronca D, Gebregziabher M, Oates JC, Egede L. Peer-to-Peer Mentoring for African American Women With Lupus: A Feasibility Pilot. Arthritis Care Res (Hoboken). 2018 06; 70(6):908-917. PMID: 29161471.
      Citations:    
    34. Turner CA, Jacobs AD, Marques CK, Oates JC, Kamen DL, Anderson PE, Obeid JS. Word2Vec inversion and traditional text classifiers for phenotyping lupus. BMC Med Inform Decis Mak. 2017 Aug 22; 17(1):126. PMID: 28830409.
      Citations:    
    35. Buie JJ, Renaud LL, Muise-Helmericks R, Oates JC. IFN-a Negatively Regulates the Expression of Endothelial Nitric Oxide Synthase and Nitric Oxide Production: Implications for Systemic Lupus Erythematosus. J Immunol. 2017 09 15; 199(6):1979-1988. PMID: 28779021.
      Citations:    
    36. Ruiz D, Oates JC, Kamen DL. Antiphospholipid Antibodies and Heart Valve Disease in Systemic Lupus Erythematosus. Am J Med Sci. 2018 03; 355(3):293-298. PMID: 29549933.
      Citations:    
    37. Williams EM, Hyer JM, Viswanathan R, Faith TD, Egede L, Oates JC, Marshall GD. Cytokine balance and behavioral intervention; findings from the Peer Approaches to Lupus Self-Management (PALS) project. Hum Immunol. 2017 Sep; 78(9):574-581. PMID: 28716698.
      Citations:    
    38. Flournoy-Floyd M, Ortiz K, Egede L, Oates JC, Faith TD, Williams EM. "We Would Still Find Things to Talk About": Assessment of Mentor Perspectives in a Systemic Lupus Erythematosus Intervention to Improve Disease Self-Management, Empowering SLE Patients. J Natl Med Assoc. 2018 Apr; 110(2):182-189. PMID: 29580453.
      Citations:    
    39. Marshall EA, Oates JC, Shoaibi A, Obeid JS, Habrat ML, Warren RW, Brady KT, Lenert LA. A population-based approach for implementing change from opt-out to opt-in research permissions. PLoS One. 2017; 12(4):e0168223. PMID: 28441388.
      Citations:    
    40. Williams EM, Egede L, Faith T, Oates J. Effective Self-Management Interventions for Patients With Lupus: Potential Impact of Peer Mentoring. Am J Med Sci. 2017 06; 353(6):580-592. PMID: 28641721.
      Citations:    
    41. Yazdany J, Bansback N, Clowse M, Collier D, Law K, Liao KP, Michaud K, Morgan EM, Oates JC, Orozco C, Reimold A, Simard JF, Myslinski R, Kazi S. Rheumatology Informatics System for Effectiveness: A National Informatics-Enabled Registry for Quality Improvement. Arthritis Care Res (Hoboken). 2016 12; 68(12):1866-1873. PMID: 27696755.
      Citations:    
    42. Williams EM, Lorig K, Glover S, Kamen D, Back S, Merchant A, Zhang J, Oates JC. Intervention to Improve Quality of life for African-AmericaN lupus patients (IQAN): study protocol for a randomized controlled trial of a unique a la carte intervention approach to self-management of lupus in African Americans. BMC Health Serv Res. 2016 08 02; 16(a):339. PMID: 27485509.
      Citations:    
    43. Wolf BJ, Spainhour JC, Arthur JM, Janech MG, Petri M, Oates JC. Development of Biomarker Models to Predict Outcomes in Lupus Nephritis. Arthritis Rheumatol. 2016 08; 68(8):1955-63. PMID: 26867033.
      Citations:    
    44. Oates JC. Presentation of the 2016 Founders' Medal Award. Am J Med Sci. 2016 07; 352(1):6-8. PMID: 27432030.
      Citations:    
    45. Barnado A, Crofford LJ, Oates JC. At the Bedside: Neutrophil extracellular traps (NETs) as targets for biomarkers and therapies in autoimmune diseases. J Leukoc Biol. 2016 Feb; 99(2):265-78. PMID: 26658004.
      Citations:    
    46. Putterman C, Wu A, Reiner-Benaim A, Batty DS, Sanz I, Oates J, Jakobi K, Petri M, Safer P, Gerwien R, Sorek R, Blumenstein Y, Cohen IR. SLE-key(®) rule-out serologic test for excluding the diagnosis of systemic lupus erythematosus: Developing the ImmunArray iCHIP(®). J Immunol Methods. 2016 Feb; 429:1-6. PMID: 26678162.
      Citations:    
    47. Kamen DL, Oates JC. A Pilot Study to Determine if Vitamin D Repletion Improves Endothelial Function in Lupus Patients. Am J Med Sci. 2015 Oct; 350(4):302-7. PMID: 26351776.
      Citations:    
    48. Mashmoushi AK, Oates JC. Lipopolysaccharide induces inducible nitric oxide synthase-dependent podocyte dysfunction via a hypoxia-inducible factor 1a and cell division control protein 42 and Ras-related C3 botulinum toxin substrate 1 pathway. Free Radic Biol Med. 2015 Jul; 84:185-195. PMID: 25765888.
      Citations:    
    49. Oates JC. Endothelial dysfunction in injury and inflammation. Am J Med Sci. 2015 Jan; 349(1):2. PMID: 25535885.
      Citations:    
    50. Sato S, Lennard Richard M, Brandon D, Jones Buie JN, Oates JC, Gilkeson GS, Zhang XK. A critical role of the transcription factor fli-1 in murine lupus development by regulation of interleukin-6 expression. Arthritis Rheumatol. 2014 Dec; 66(12):3436-44. PMID: 25155007.
      Citations:    
    51. Williams EM, Bruner L, Penfield M, Kamen D, Oates JC. Stress and Depression in Relation to Functional Health Behaviors in African American Patients with Systemic Lupus Erythematosus. Rheumatology (Sunnyvale). 2014; 2014(Suppl 4). PMID: 26618072.
      Citations:    
    52. Nowling TK, Mather AR, Thiyagarajan T, Hernández-Corbacho MJ, Powers TW, Jones EE, Snider AJ, Oates JC, Drake RR, Siskind LJ. Renal glycosphingolipid metabolism is dysfunctional in lupus nephritis. J Am Soc Nephrol. 2015 Jun; 26(6):1402-13. PMID: 25270066.
      Citations:    
    53. Afrin LB, Oates JC, Kamen DL. Improving clinical trial accrual by streamlining the referral process. Int J Med Inform. 2015 Jan; 84(1):15-23. PMID: 25256066.
      Citations:    
    54. Jones Buie JN, Oates JC. Role of interferon alpha in endothelial dysfunction: insights into endothelial nitric oxide synthase-related mechanisms. Am J Med Sci. 2014 Aug; 348(2):168-75. PMID: 24796291.
      Citations:    
    55. Williams EM, Zhang J, Zhou J, Kamen D, Oates JC. Predictors of non-response and non-compliance in African American lupus patients: Findings from the Balancing Lupus Experiences with Stress Strategies (BLESS) Study. Int J Med Biomed Sci. 2014 Feb; 2(1):6-19. PMID: 25664344.
      Citations:    
    56. Williams EM, Penfield M, Kamen D, Oates JC. An Intervention to Reduce Psychosocial and Biological Indicators of Stress in African American Lupus Patients: The Balancing Lupus Experiences with Stress Strategies Study. Open J Prev Med. 2014 Jan; 4(1):22-31. PMID: 24999444.
      Citations:    
    57. Williams EM, Kamen D, Penfield M, Oates JC. Stress Intervention and Disease in African American Lupus Patients: The Balancing Lupus Experiences with Stress Strategies (BLESS) Study. Health (Irvine Calif). 2014 Jan; 6(1):71-79. PMID: 24932382.
      Citations:    
    58. Oates JC, Mashmoushi AK, Shaftman SR, Gilkeson GS. NADPH oxidase and nitric oxide synthase-dependent superoxide production is increased in proliferative lupus nephritis. Lupus. 2013 Nov; 22(13):1361-70. PMID: 24106214.
      Citations:    
    59. Reese C, Dyer S, Perry B, Bonner M, Oates J, Hofbauer A, Sessa W, Bernatchez P, Visconti RP, Zhang J, Hatfield CM, Silver RM, Hoffman S, Tourkina E. Differential regulation of cell functions by CSD peptide subdomains. Respir Res. 2013 Sep 08; 14:90. PMID: 24011378.
      Citations:    
    60. Gilkeson GS, Mashmoushi AK, Ruiz P, Caza TN, Perl A, Oates JC. Endothelial nitric oxide synthase reduces crescentic and necrotic glomerular lesions, reactive oxygen production, and MCP1 production in murine lupus nephritis. PLoS One. 2013; 8(5):e64650. PMID: 23741359.
      Citations:    
    61. Ramos PS, Oates JC, Kamen DL, Williams AH, Gaffney PM, Kelly JA, Kaufman KM, Kimberly RP, Niewold TB, Jacob CO, Tsao BP, Alarcón GS, Brown EE, Edberg JC, Petri MA, Ramsey-Goldman R, Reveille JD, Vilá LM, James JA, Guthridge JM, Merrill JT, Boackle SA, Freedman BI, Scofield RH, Stevens AM, Vyse TJ, Criswell LA, Moser KL, Alarcón-Riquelme ME, Langefeld CD, Harley JB, Gilkeson GS. Variable association of reactive intermediate genes with systemic lupus erythematosus in populations with different African ancestry. J Rheumatol. 2013 Jun; 40(6):842-9. PMID: 23637325.
      Citations:    
    62. Snider AJ, Ruiz P, Obeid LM, Oates JC. Inhibition of sphingosine kinase-2 in a murine model of lupus nephritis. PLoS One. 2013; 8(1):e53521. PMID: 23301082.
      Citations:    
    63. Ravenell RL, Kamen DL, Spence JD, Hollis BW, Fleury TJ, Janech MG, Almeida JS, Shaftman SR, Oates JC. Premature atherosclerosis is associated with hypovitaminosis D and angiotensin-converting enzyme inhibitor non-use in lupus patients. Am J Med Sci. 2012 Oct; 344(4):268-73. PMID: 22222338.
      Citations:    
    64. Al Gadban MM, German J, Truman JP, Soodavar F, Riemer EC, Twal WO, Smith KJ, Heller D, Hofbauer AF, Oates JC, Hammad SM. Lack of nitric oxide synthases increases lipoprotein immune complex deposition in the aorta and elevates plasma sphingolipid levels in lupus. Cell Immunol. 2012 Mar-Apr; 276(1-2):42-51. PMID: 22560558.
      Citations:    
    65. Taylor TP, Janech MG, Slate EH, Lewis EC, Arthur JM, Oates JC. Overcoming the effects of matrix interference in the measurement of urine protein analytes. Biomark Insights. 2012; 7:1-8. PMID: 22403482.
      Citations:    
    66. Tourkina E, Bonner M, Oates J, Hofbauer A, Richard M, Znoyko S, Visconti RP, Zhang J, Hatfield CM, Silver RM, Hoffman S. Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide. Fibrogenesis Tissue Repair. 2011 Jul 01; 4(1):15. PMID: 21722364.
      Citations:    
    67. Oates JC, Halushka PV, Hutchison FN, Ruiz P, Gilkeson GS. Selective cyclooxygenase-2 inhibitor suppresses renal thromboxane production but not proliferative lesions in the MRL/lpr murine model of lupus nephritis. Am J Med Sci. 2011 Feb; 341(2):101-5. PMID: 20924284.
      Citations:    
    68. Tourkina E, Richard M, Oates J, Hofbauer A, Bonner M, Gööz P, Visconti R, Zhang J, Znoyko S, Hatfield CM, Silver RM, Hoffman S. Caveolin-1 regulates leucocyte behaviour in fibrotic lung disease. Ann Rheum Dis. 2010 Jun; 69(6):1220-6. PMID: 20410070.
      Citations:    
    69. Oates JC. The biology of reactive intermediates in systemic lupus erythematosus. Autoimmunity. 2010 Feb; 43(1):56-63. PMID: 20001422.
      Citations:    
    70. Qin Z, Freitas E, Sullivan R, Mohan S, Bacelieri R, Branch D, Romano M, Kearney P, Oates J, Plaisance K, Renne R, Kaleeba J, Parsons C. Upregulation of xCT by KSHV-encoded microRNAs facilitates KSHV dissemination and persistence in an environment of oxidative stress. PLoS Pathog. 2010 Jan 29; 6(1):e1000742. PMID: 20126446.
      Citations:    
    71. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 Jan; 62(1):222-33. PMID: 20039413.
      Citations:    
    72. Scofield RH, Oates J. The place of William Osler in the description of systemic lupus erythematosus. Am J Med Sci. 2009 Nov; 338(5):409-12. PMID: 19826244.
      Citations:    
    73. Andrews N, Burris JE, Cech TR, Coller BS, Crowley WF, Gallin EK, Kelner KL, Kirch DG, Leshner AI, Morris CD, Nguyen FT, Oates J, Sung NS. Translational careers. Science. 2009 May 15; 324(5929):855. PMID: 19443750.
      Citations:    
    74. Njoku C, Self SE, Ruiz P, Hofbauer AF, Gilkeson GS, Oates JC. Inducible nitric oxide synthase inhibitor SD-3651 reduces proteinuria in MRL/lpr mice deficient in the NOS2 gene. J Investig Med. 2008 Oct; 56(7):911-9. PMID: 18797415.
      Citations:    
    75. Evans JT, Shepard MM, Oates JC, Self SE, Reuben A. Rituximab-responsive cryoglobulinemic glomerulonephritis in a patient with autoimmune hepatitis. J Clin Gastroenterol. 2008 Aug; 42(7):862-3. PMID: 18458643.
      Citations:    
    76. Oates JC, Shaftman SR, Self SE, Gilkeson GS. Association of serum nitrate and nitrite levels with longitudinal assessments of disease activity and damage in systemic lupus erythematosus and lupus nephritis. Arthritis Rheum. 2008 Jan; 58(1):263-72. PMID: 18163495.
      Citations:    
    77. Oates JC, Farrelly LW, Hofbauer AF, Wang W, Gilkeson GS. Association of reactive oxygen and nitrogen intermediate and complement levels with apoptosis of peripheral blood mononuclear cells in lupus patients. Arthritis Rheum. 2007 Nov; 56(11):3738-47. PMID: 17968874.
      Citations:    
    78. Bouali H, Nietert P, Nowling TM, Pandey J, Dooley MA, Cooper G, Harley J, Kamen DL, Oates J, Gilkeson G. Association of the G-463A myeloperoxidase gene polymorphism with renal disease in African Americans with systemic lupus erythematosus. J Rheumatol. 2007 Oct; 34(10):2028-34. PMID: 17896805.
      Citations:    
    79. Yu L, Wang J, O'Dell JR, Oates J, Arend WP, Eisenbarth GS. Anti-dsDNA antibody assay: high specificity and sensitivity with a filtration radioassay in comparison to low specificity with the standard ELISA. J Rheumatol. 2007 Apr; 34(4):734-9. PMID: 17407230.
      Citations:    
    80. Varghese SA, Powell TB, Budisavljevic MN, Oates JC, Raymond JR, Almeida JS, Arthur JM. Urine biomarkers predict the cause of glomerular disease. J Am Soc Nephrol. 2007 Mar; 18(3):913-22. PMID: 17301191.
      Citations:    
    81. Oates J. Renal biopsy at the onset of clinical lupus nephritis: can it yield useful information? J Rheumatol. 2007 Feb; 34(2):256-8. PMID: 17304650.
      Citations:    
    82. Oates JC, Gilkeson GS. The biology of nitric oxide and other reactive intermediates in systemic lupus erythematosus. Clin Immunol. 2006 Dec; 121(3):243-50. PMID: 16861040.
      Citations:    
    83. Oates JC, Varghese S, Bland AM, Taylor TP, Self SE, Stanislaus R, Almeida JS, Arthur JM. Prediction of urinary protein markers in lupus nephritis. Kidney Int. 2005 Dec; 68(6):2588-92. PMID: 16316334.
      Citations:    
    84. Njoku CJ, Patrick KS, Ruiz P, Oates JC. Inducible nitric oxide synthase inhibitors reduce urinary markers of systemic oxidant stress in murine proliferative lupus nephritis. J Investig Med. 2005 Nov; 53(7):347-52. PMID: 16297360.
      Citations:    
    85. Donovan JL, DeVane CL, Chavin KD, Oates JC, Njoku C, Patrick KS, Fiorini RN, Markowitz JS. Oral administration of a decaffeinated green tea (Camellia sinensis) extract did not alter urinary 8-epi-prostaglandin F(2 alpha), a biomarker for in-vivo lipid peroxidation. J Pharm Pharmacol. 2005 Oct; 57(10):1365-9. PMID: 16259767.
      Citations:    
    86. Bogatkevich GS, Gustilo E, Oates JC, Feghali-Bostwick C, Harley RA, Silver RM, Ludwicka-Bradley A. Distinct PKC isoforms mediate cell survival and DNA synthesis in thrombin-induced myofibroblasts. Am J Physiol Lung Cell Mol Physiol. 2005 Jan; 288(1):L190-201. PMID: 15447940.
      Citations:    
    87. Tourkina E, Gooz P, Oates JC, Ludwicka-Bradley A, Silver RM, Hoffman S. Curcumin-induced apoptosis in scleroderma lung fibroblasts: role of protein kinase cepsilon. Am J Respir Cell Mol Biol. 2004 Jul; 31(1):28-35. PMID: 14742295.
      Citations:    
    88. Oates JC, Gilkeson GS. Nitric oxide induces apoptosis in spleen lymphocytes from MRL/lpr mice. J Investig Med. 2004 Jan; 52(1):62-71. PMID: 14989372.
      Citations:    
    89. Oates JC, Levesque MC, Hobbs MR, Smith EG, Molano ID, Page GP, Hill BS, Weinberg JB, Cooper GS, Gilkeson GS. Nitric oxide synthase 2 promoter polymorphisms and systemic lupus erythematosus in african-americans. J Rheumatol. 2003 Jan; 30(1):60-7. PMID: 12508391.
      Citations:    
    90. Afrin LB, Oates JC, Boyd CK, Daniels MS. Leveraging of open EMR architecture for clinical trial accrual. AMIA Annu Symp Proc. 2003; 16-20. PMID: 14728125.
      Citations:    
    91. Oates JC, Gilkeson GS. Mediators of injury in lupus nephritis. Curr Opin Rheumatol. 2002 Sep; 14(5):498-503. PMID: 12192244.
      Citations:    
    92. Oates JC, Reilly CM, Crosby MB, Gilkeson GS. Peroxisome proliferator-activated receptor gamma agonists: potential use for treating chronic inflammatory diseases. Arthritis Rheum. 2002 Mar; 46(3):598-605. PMID: 11920394.
      Citations:    
    93. Reilly CM, Oates JC, Sudian J, Crosby MB, Halushka PV, Gilkeson GS. Prostaglandin J(2) inhibition of mesangial cell iNOS expression. Clin Immunol. 2001 Mar; 98(3):337-45. PMID: 11237557.
      Citations:    
    94. Crofford LJ, Oates JC, McCune WJ, Gupta S, Kaplan MJ, Catella-Lawson F, Morrow JD, McDonagh KT, Schmaier AH. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases. Arthritis Rheum. 2000 Aug; 43(8):1891-6. PMID: 10943882.
      Citations:    
    95. Reilly CM, Oates JC, Cook JA, Morrow JD, Halushka PV, Gilkeson GS. Inhibition of mesangial cell nitric oxide in MRL/lpr mice by prostaglandin J2 and proliferator activation receptor-gamma agonists. J Immunol. 2000 Feb 01; 164(3):1498-504. PMID: 10640767.
      Citations:    
    96. Oates JC, Christensen EF, Reilly CM, Self SE, Gilkeson GS. Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus: correlation with disease activity. Proc Assoc Am Physicians. 1999 Nov-Dec; 111(6):611-21. PMID: 10591091.
      Citations:    
    97. Orr RK, Hoehn JL, Col NF. The learning curve for sentinel node biopsy in breast cancer: practical considerations. Arch Surg. 1999 Jul; 134(7):764-7. PMID: 27651918.
      Citations:    
    98. Orr RK, Hoehn JL, Col NF. The learning curve for sentinel node biopsy in breast cancer: practical considerations. Arch Surg. 1999 Jul; 134(7):764-7. PMID: 31106972.
      Citations:    
    99. Orr RK, Hoehn JL, Col NF. The learning curve for sentinel node biopsy in breast cancer: practical considerations. Arch Surg. 1999 Jul; 134(7):764-7. PMID: 23531953.
      Citations:    
    100. Gilkeson G, Cannon C, Oates J, Reilly C, Goldman D, Petri M. Correlation of serum measures of nitric oxide production with lupus disease activity. J Rheumatol. 1999 Feb; 26(2):318-24. PMID: 9972965.
      Citations:    
    101. Oates JC, Ruiz P, Alexander A, Pippen AM, Gilkeson GS. Effect of late modulation of nitric oxide production on murine lupus. Clin Immunol Immunopathol. 1997 Apr; 83(1):86-92. PMID: 9073540.
      Citations:    
    102. Woosley RL, Roden DM, Dai GH, Wang T, Altenbern D, Oates J, Wilkinson GR. Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. Clin Pharmacol Ther. 1986 Mar; 39(3):282-7. PMID: 3081292.
      Citations:    
    Oates's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (455)
    Explore
    _
    Co-Authors (63)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _